Injection Of Fibrin Sealant Including An Anesthetic In Spinal Applications

Abstract

A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus. The method includes injecting a fibrin sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises an anesthetic, fibrinogen and an activating compound, wherein at least a portion of the fibrin forms after injection, with the proviso that a corticosteroid is absent from the fibrin sealant injected into the disc.

What is claimed is: 
     
         1 . A kit, comprising: a fibrinogen, thrombin, a spinal needle, and an introducer needle, wherein spinal needle is of a length that does not extend past the tip of an introducer needle during use, wherein the kit excludes corticosteroid and wherein the kit excludes a device to provide thermal energy to a disc. 
     
     
         2 . The kit of  claim 1 , further comprising: one of lidocaine, sarapin or bupivicaine. 
     
     
         3 . The kit of  claim 1 , further comprising calcium chloride. 
     
     
         4 . The kit of  claim 1 , further comprising an additive, wherein the additive is selected from the group consisting of antibiotics; antiproliferative, cytotoxic, and antitumor drugs; analgesic; antiangiogen; antivirals; cytokines; colony stimulating factors; proteins; chemoattractants; EDTA; histamine; antihistamine; erythropoietin; antifungals; antiparasitic agents; non-corticosteroid anti-inflammatory agents; anticoagulants; oncology agents; cardiovascular drugs; glycoproteins; fibronectin; interferons; cartilage inducing factors; protease inhibitors; vasoconstrictors, vasodilators, demineralized bone or bone morphogenetic proteins; hormones; lipids; carbohydrates; proteoglycans; antiangiogenins; antigens; DBM; hyaluronic acid and salts thereof; polysaccharides; cellulose compounds; antibodies; gene therapy reagents; genetically altered cells, stem cells and/or other cells; cell growth factors; type II collagen; collagen hydrolyzate; elastin; sulfated glycosaminoglycan (sGAG), glucosamine sulfate; pH modifiers; methylsulfonylmethane (MSM); osteogenic compounds; osteoconductive compounds; plasminogen; nucleotides; oligonucleotides; polynucleotides; polymers; osteogenic protein 1 (OP-1); LMP-1 (Lim Mineralization Protein-1); cartilage; oxygen-containing components; enzymes; melatonin; vitamins; and nutrients. 
     
     
         5 . The kit of  claim 1 , wherein the fibrinogen and thrombin are in a freeze-dried state. 
     
     
         6 . The kit of  claim 1 , further comprising calcium chloride. 
     
     
         7 . The kit of  claim 1 , further comprising a dual barrel syringe. 
     
     
         8 . The kit of  claim 1 , further comprising an additive. 
     
     
         9 . The kit of  claim 1 , wherein the fibrinogen is in a frozen state and the thrombin is in a frozen state.